| |
|
|
|
|
|
|
|||
|
Blood, 15 December 2007, Vol. 110, No. 13, pp. 4319-4330. Prepublished online as a Blood First Edition Paper on September 11, 2007; DOI 10.1182/blood-2007-02-072587.
IMMUNOBIOLOGY Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells1 Inserm, U564, Equipe Avenir, Angers; 2 Université d'Angers, Unité Mixte de Recherche–Santé (UMR-S) 564, Angers; 3 Université d'Angers, Unité Propre de Recherche de l'Enseignement Supérieur (UPRES) EA3863, Angers; 4 Centre Hospitalier Universitaire (CHU) d'Angers, Département des maladies du sang, Angers; 5 Inserm, U564, Angers; 6 Inserm UMR 643, Nantes; 7 Université de Nantes, Institut de Transplantation et de Recherche en Transplantation, Federation of Clinical Immunology Societies (FOCIS), Nantes; 8 CHU d'Angers, Département de Gynécologie, Angers; 9 Centre de lutte contre le Cancer Paul Papin, Angers; 10 CHU de Lille, Département d'Oncologie, Lille; and 11 CHU d'Angers, Laboratoire d'Immunologie et d'Allergologie, Angers, France Tumor-associated macrophages (TAMs), the most abundant immunosuppressive cells in the tumor microenvironment, originate from blood monocytes and exhibit an IL-10highIL-12low M2 profile. The factors involved in TAM generation remain unidentified. We identify here leukemia inhibitory factor (LIF) and IL-6 as tumor microenvironmental factors that can promote TAM generation. Ovarian cancer ascites switched monocyte differentiation into TAM-like cells that exhibit most ovarian TAM functional and phenotypic characteristics. Ovarian cancer ascites contained high concentrations of LIF and IL-6. Recombinant LIF and IL-6 skew monocyte differentiation into TAM-like cells by enabling monocytes to consume monocyte–colony-stimulating factor (M-CSF). Depletion of LIF, IL-6, and M-CSF in ovarian cancer ascites suppressed TAM-like cell induction. We extended these observations to different tumor-cell line supernatants. In addition to revealing a new tumor-escape mechanism associated with TAM generation via LIF and IL-6, these findings offer novel therapeutic perspectives to subvert TAM-induced immunosuppression and hence improve T-cell–based antitumor immunotherapy efficacy.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||